TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TGCT) IN THE UNITED STATES
Author(s)
Nicholas Bernthal, MD1, Samuel Wagner, PhD2, Precious Nchekwube, MPH3, Jialu He, MPH3, Nehir Yapar, BE3, Wanlin Guo, MS3, Yijia Sun, MS3, Amy Phillips, PharmD4, Carroline Lobo, PhD4, Boris Pfeiffer, MD, PhD, MSc5.
1Division of Musculoskeletal Oncology, David Geffen School of Medicine at UCLA, Santa Monica, CA, USA, 2Columbia Data Analytics, Newtown, PA, USA, 3Columbia Data Analytics, New York, NY, USA, 4North America Evidence & Value Development, EMD Serono, Inc, Boston, MA, USA, an affiliate of Merck KGaA, Boston, MA, USA, 5Global Value Access and Pricing, Merck Healthcare KGaA, Darmstadt, Germany, Darmstadt, Germany.
1Division of Musculoskeletal Oncology, David Geffen School of Medicine at UCLA, Santa Monica, CA, USA, 2Columbia Data Analytics, Newtown, PA, USA, 3Columbia Data Analytics, New York, NY, USA, 4North America Evidence & Value Development, EMD Serono, Inc, Boston, MA, USA, an affiliate of Merck KGaA, Boston, MA, USA, 5Global Value Access and Pricing, Merck Healthcare KGaA, Darmstadt, Germany, Darmstadt, Germany.
OBJECTIVES: Tenosynovial Giant Cell Tumor (TGCT) is a rare, locally aggressive soft-tissue tumor with potentially devastating morbidity. This study evaluated treatment patterns, healthcare resource utilization (HCRU), and costs in patients with TGCT in the United States.
METHODS: This study used Kythera Labs commercial claims database to identify adults (18-64 years) with localized (L-TGCT) or diffuse TGCT (D-TGCT) between January 2019 and December 2025. Patients were identified using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. Patients required ≥1 inpatient/emergency department claim or ≥2 outpatient claims ≥30 days apart and ≥12 months of continuous enrolment before and after the index date. Patients with evidence of pre-index malignant sarcoma or desmoid tumors were excluded. Treatment patterns, HCRU, and costs were assessed overall and stratified by TGCT subtype. Propensity score matching (PSM) was performed between TGCT patients and non-TGCT controls to compare all-cause HCRU and costs.
RESULTS: There were 24,718 L-TGCT and 4,331 D-TGCT patients. Overall, 42.1% patients had surgery, with a higher proportion in D-TGCT (57.0%) vs. L-TGCT (39.4%). Supplemental care (38.1%), diagnostic imaging (46.8%), opioid use (49.1%), and NSAIDs use (43.2%) were also observed. In the 12-month post-index period, D-TGCT had higher TGCT-related HCRU than L-TGCT (outpatient visits: 4.2 vs. 3.2 per person per year [PPPY]). Total TGCT-related follow-up costs were over 4-times higher in D-TGCT vs. L-TGCT ($26,497 vs. $6,232 PPPY). After PSM, D-TGCT demonstrated the highest all-cause HCRU, with 16.7 outpatient visits PPPY compared with 14.2 in L-TGCT and 5.9 in matched controls. D-TGCT patients incurred the highest all-cause follow-up costs ($42,119 PPPY) compared to L-TGCT ($22,521 PPPY) and matched controls ($8,983 PPPY). Outpatient visits accounted for the largest share of costs (D-TGCT [$36,175 PPPY]; L-TGCT [$15,680 PPPY]; matched controls $3,683 PPPY]).
CONCLUSIONS: There was substantial economic burden and HCRU in TGCT, driven primarily by outpatient care.
METHODS: This study used Kythera Labs commercial claims database to identify adults (18-64 years) with localized (L-TGCT) or diffuse TGCT (D-TGCT) between January 2019 and December 2025. Patients were identified using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. Patients required ≥1 inpatient/emergency department claim or ≥2 outpatient claims ≥30 days apart and ≥12 months of continuous enrolment before and after the index date. Patients with evidence of pre-index malignant sarcoma or desmoid tumors were excluded. Treatment patterns, HCRU, and costs were assessed overall and stratified by TGCT subtype. Propensity score matching (PSM) was performed between TGCT patients and non-TGCT controls to compare all-cause HCRU and costs.
RESULTS: There were 24,718 L-TGCT and 4,331 D-TGCT patients. Overall, 42.1% patients had surgery, with a higher proportion in D-TGCT (57.0%) vs. L-TGCT (39.4%). Supplemental care (38.1%), diagnostic imaging (46.8%), opioid use (49.1%), and NSAIDs use (43.2%) were also observed. In the 12-month post-index period, D-TGCT had higher TGCT-related HCRU than L-TGCT (outpatient visits: 4.2 vs. 3.2 per person per year [PPPY]). Total TGCT-related follow-up costs were over 4-times higher in D-TGCT vs. L-TGCT ($26,497 vs. $6,232 PPPY). After PSM, D-TGCT demonstrated the highest all-cause HCRU, with 16.7 outpatient visits PPPY compared with 14.2 in L-TGCT and 5.9 in matched controls. D-TGCT patients incurred the highest all-cause follow-up costs ($42,119 PPPY) compared to L-TGCT ($22,521 PPPY) and matched controls ($8,983 PPPY). Outpatient visits accounted for the largest share of costs (D-TGCT [$36,175 PPPY]; L-TGCT [$15,680 PPPY]; matched controls $3,683 PPPY]).
CONCLUSIONS: There was substantial economic burden and HCRU in TGCT, driven primarily by outpatient care.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE213
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology, Rare & Orphan Diseases